Inhibrx Biosciences, Inc.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company based in La Jolla, California. It develops biologic therapeutic candidates using its modular protein engineering platforms, with a focus on treatments for people with life-threatening conditions. Inhibrx’s clinical pipeline focuses on oncology. Ozekibart (INBRX-109) is a DR5 agonist being investigated in chondrosarcoma, Ewing sarcoma, colorectal cancer and other solid tumors. INBRX-106 is an OX40 agonist being investigated in patients with non-small cell lung cancer and head and neck squamous cell carcinoma, including in combination with KEYTRUDA. The company also has a discovery pipeline and in-house capabilities spanning protein engineering, clinical development and commercialization.
No SEC Form 4 filings for $INBX in the last 30 days.
See all $INBX insider activity →Inhibrx Biosciences (INBX) reported Q3 2026 financial results, with $2.0M revenue from a Pfizer license agreement, $199.5M in cash, and a net loss of $38.7M. The company is advancing clinical trials for ozekibart (INBRX-109) in Ewing sarcoma and chondrosarcoma, and ordastobart (INBRX-106) in HNSCC and NSCLC. R&D expenses decreased to $26.0M, while G&A and other expenses increased.
Lappe Mark (Chief Executive Officer) purchased 10,040 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $84.56 ($84.07–$85.76, $0.85M total) across 6 trades on 2026-10-14.
Inhibrx Biosciences (INBX) will present updated data on INBRX-106 and INBRX-109 at global oncology conferences. The presentations aim to validate mid-stage data and influence investor sentiment. The company faces risks including heavy losses and reliance on external financing, with shares potentially trading at a premium according to a valuation report.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning INBX (Inhibrx Biosciences, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 5 bearish.
Recent INBX coverage spans insider activity, financial news and earnings.
Earnings miss and widening loss likely pressure the stock lower, though strong cash may limit downside.
Insider buying suggests confidence and may support the stock price.
The stock may experience short‑term volatility as investors price in the upcoming data.
The insider purchase suggests confidence from management and may create modest buying pressure.
Positive trial data de‑risk the program but the unexpected price decline suggests short‑term sell pressure.
AlphAI scores every news story that mentions INBX with an AI model for sentiment and relevance, and aggregates insider trades from Inhibrx Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Inhibrx Biosciences (INBX) reported Q3 2026 financial results, with $2.0M revenue from a Pfizer license agreement, $199.5M in cash, and a net loss of $38.7M. The company is advancing clinical trials for ozekibart (INBRX-109) in Ewing sarcoma and chondrosarcoma, and ordastobart (INBRX-106) in HNSCC and NSCLC. R&D expenses decreased to $26.0M, while G&A and other expenses increased.
Lappe Mark (Chief Executive Officer) purchased 10,040 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $84.56 ($84.07–$85.76, $0.85M total) across 6 trades on 2026-10-14.
Inhibrx Biosciences (INBX) will present updated data on INBRX-106 and INBRX-109 at global oncology conferences. The presentations aim to validate mid-stage data and influence investor sentiment. The company faces risks including heavy losses and reliance on external financing, with shares potentially trading at a premium according to a valuation report.
Lappe Mark (Chief Executive Officer) purchased 10,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $99.88 ($98.87–$101.70, $1.00M total) across 4 trades over 2026-09-25 to 2026-09-28.
Inhibrx Biosciences reported that its experimental cancer drug INBRX-106, combined with Merck's Keytruda, achieved a 48.3% response rate in a Phase 2 study, nearly double Keytruda's 26.5% alone. The stock fell 8.8% to $110.45 despite the positive data, with the company planning to expand the study for HPV-positive patients, according to Reuters.
CapsoVision (CV) director bought $9.9M shares at $5.69 each. Corebridge (CRBG) 10% owner Nippon Life bought $7.47M shares at $35.08. Inhibrx (INBX) director bought $500K shares at $100. Diamondback (FANG) director sold $15.32M shares at $204.31. Arista (ANET) CTO sold $8.82M shares near 52-week high. Duolingo (DUOL) CEO sold $6.17M shares at $150-$152. Asana (ASAN) CEO sold $4.2M shares. Robinhood (HOOD) CEO sold $32.55M shares.
Kayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $100.00 ($0.50M total) on 2026-09-23.
On September 15-16, 2026, insiders made notable transactions: Avenue RP Opportunities Fund and director Par Chadha bought XBP Global Holdings (XBP) shares at $2.83 each, totaling $1.5M and $580K respectively. Directors at Agree Realty (ADC) bought shares near its 52-week low. A director at Inhibrx (INBX) bought 5K shares at $100 each. A director at CrowdStrike (CRWD) sold 119K shares for $28.6M. Silver Lake Partners sold Dell (DELL) shares for $28M. A 10% owner of Talos Energy (TALO) sold 1.38M
Kayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $100.00 ($0.50M total) on 2026-09-16.
MANHARD KIMBERLY sold 1,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $109.03 ($105.05–$111.78, $0.16M total) across 3 trades over 2026-09-11 to 2026-09-15.
